PortfoliosLab logoPortfoliosLab logo
AZN vs. SHEL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AZN vs. SHEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AstraZeneca PLC (AZN) and Shell plc (SHEL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AZN achieves a 0.81% return, which is significantly lower than SHEL's 20.10% return. Over the past 10 years, AZN has outperformed SHEL with an annualized return of 15.85%, while SHEL has yielded a comparatively lower 10.03% annualized return.


AZN

1D
-2.37%
1M
-0.71%
YTD
0.81%
6M
1.53%
1Y
28.04%
3Y*
9.54%
5Y*
12.08%
10Y*
15.85%

SHEL

1D
1.46%
1M
4.13%
YTD
20.10%
6M
21.39%
1Y
32.28%
3Y*
18.69%
5Y*
23.01%
10Y*
10.03%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AZN vs. SHEL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AZN
AstraZeneca PLC
0.81%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%
SHEL
Shell plc
20.10%22.16%-0.87%20.19%36.18%34.27%-41.08%6.38%-7.23%21.67%

Correlation

The correlation between AZN and SHEL is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.04

Correlation (3Y)
Calculated over the trailing 3-year period

0.10

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (10Y)
Calculated over the trailing 10-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Jul 21, 2005

0.32

Over the past year, the correlation between AZN and SHEL has dropped to 0.04 - well below their long-term average of 0.32, suggesting their price drivers have been diverging.

Fundamentals

Market Cap

AZN:

$283.40B

SHEL:

$247.11B

EPS

AZN:

$6.66

SHEL:

$6.39

PE Ratio

AZN:

27.27

SHEL:

13.55

PEG Ratio

AZN:

0.04

SHEL:

0.68

PS Ratio

AZN:

4.69

SHEL:

0.95

PB Ratio

AZN:

5.99

SHEL:

1.42

Total Revenue (TTM)

AZN:

$60.44B

SHEL:

$266.82B

Gross Profit (TTM)

AZN:

$49.37B

SHEL:

$41.65B

EBITDA (TTM)

AZN:

$20.47B

SHEL:

$57.44B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AZN vs. SHEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AZN
AZN Risk / Return Rank: 7373
Overall Rank
AZN Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7373
Sortino Ratio Rank
AZN Omega Ratio Rank: 6969
Omega Ratio Rank
AZN Calmar Ratio Rank: 7474
Calmar Ratio Rank
AZN Martin Ratio Rank: 7676
Martin Ratio Rank

SHEL
SHEL Risk / Return Rank: 8181
Overall Rank
SHEL Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
SHEL Sortino Ratio Rank: 7777
Sortino Ratio Rank
SHEL Omega Ratio Rank: 7676
Omega Ratio Rank
SHEL Calmar Ratio Rank: 8383
Calmar Ratio Rank
SHEL Martin Ratio Rank: 8585
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AZN vs. SHEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and Shell plc (SHEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AZNSHELDifference
Sharpe ratioReturn per unit of total volatility

-0.43

Sortino ratioReturn per unit of downside risk

-0.25

Omega ratioGain probability vs. loss probability

1.21

1.26

-0.05

Calmar ratioReturn relative to maximum drawdown

1.83

3.00

-1.17

Martin ratioReturn relative to average drawdown

4.90

8.40

-3.50

AZN vs. SHEL - Sharpe Ratio Comparison

The current AZN Sharpe Ratio is 1.11, which is comparable to the SHEL Sharpe Ratio of 1.54. The chart below compares the historical Sharpe Ratios of AZN and SHEL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


AZNSHELDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.11

1.54

-0.43

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.51

0.92

-0.41

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.64

0.33

+0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

0.49

0.22

+0.27

Drawdowns

AZN vs. SHEL - Drawdown Comparison

The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum SHEL drawdown of -71.57%. Use the drawdown chart below to compare losses from any high point for AZN and SHEL.


Loading charts...

Drawdown Indicators


AZNSHELDifference

Max Drawdown

Largest peak-to-trough decline

-48.94%

-71.57%

+22.63%

Max Drawdown (1Y)

Largest decline over 1 year

-15.43%

-10.81%

-4.62%

Max Drawdown (3Y)

Largest decline over 3 years

-27.87%

-18.47%

-9.40%

Max Drawdown (5Y)

Largest decline over 5 years

-27.87%

-25.04%

-2.83%

Max Drawdown (10Y)

Largest decline over 10 years

-27.87%

-71.57%

+43.70%

Current Drawdown

Current decline from peak

-12.90%

-7.13%

-5.77%

Average Drawdown

Average peak-to-trough decline

-11.37%

-16.74%

+5.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.75%

3.85%

+1.90%

Volatility

AZN vs. SHEL - Volatility Comparison

AstraZeneca PLC (AZN) has a higher volatility of 7.42% compared to Shell plc (SHEL) at 5.98%. This indicates that AZN's price experiences larger fluctuations and is considered to be riskier than SHEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AZNSHELDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.42%

5.98%

+1.44%

Volatility (6M)

Calculated over the trailing 6-month period

17.47%

17.50%

-0.03%

Volatility (1Y)

Calculated over the trailing 1-year period

25.55%

21.15%

+4.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.02%

25.22%

-1.20%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.94%

30.84%

-5.90%

Dividends

AZN vs. SHEL - Dividend Comparison

AZN's dividend yield for the trailing twelve months is around 2.93%, less than SHEL's 3.41% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
2.93%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
SHEL
Shell plc
3.41%3.90%4.39%3.76%3.48%3.78%5.69%6.27%6.27%2.75%6.49%8.17%

Financials

AZN vs. SHEL - Financials Comparison

This section allows you to compare key financial metrics between AstraZeneca PLC and Shell plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
15.29B
69.57B
(AZN) Total Revenue
(SHEL) Total Revenue
Values in USD except per share items

AZN vs. SHEL - Profitability Comparison

The chart below illustrates the profitability comparison between AstraZeneca PLC and Shell plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
82.5%
19.1%
Portfolio components
AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

SHEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Shell plc reported a gross profit of 13.31B and revenue of 69.57B. Therefore, the gross margin over that period was 19.1%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

SHEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Shell plc reported an operating income of 10.35B and revenue of 69.57B, resulting in an operating margin of 14.9%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.

SHEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Shell plc reported a net income of 5.68B and revenue of 69.57B, resulting in a net margin of 8.2%.


Frequently Asked Questions


AZN and SHEL have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AZN has higher volatility (7.42%) compared to SHEL (5.98%). In terms of maximum drawdown, AZN dropped -48.94% vs SHEL's -71.57%.

SHEL currently has the higher Sharpe Ratio (1.54 vs 1.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AZN and SHEL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer